StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Wednesday morning. The firm issued a sell rating on the stock. ONCT has been the topic of a number of other reports. Cantor Fitzgerald reissued a neutral rating and issued a $1.30 target price on shares of […]
A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.
StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report issued on Monday. The brokerage issued a sell rating on the stock. Several other research firms also recently weighed in on ONCT. HC Wainwright upgraded shares of Oncternal Therapeutics from a neutral rating to a buy rating and set a […]
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Monday morning. The brokerage issued a sell rating on the stock. Several other analysts have also recently commented on ONCT. HC Wainwright upgraded shares of Oncternal Therapeutics from a neutral rating to a buy rating and set […]
StockNews com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.